Influenza Therapeutics Market: Restraints
Influenza vaccines have several limitations including relatively long production times, limited vaccine capacity, moderate efficacy in certain people, and lack of cross-reactivity, which is projected to restrain growth of the influenza therapeutic market during the forecast period. Moreover, increasing concerns among people about the side effects of vaccines hamper growth of the influenza therapeutic market. For instance, in October 2018, according to the National Opinion Research Centre (NORC) at the University of Chicago survey, around 43% of the adults were vaccinated and 14% plans to receive the flu shot. However, around 41% of the American people reported that they are not vaccinated and do not intend to get vaccinated, as adults were most likely to cite concerns about side effects of the vaccine.
Influenza Therapeutics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients